Adeno-Associated Virus-Mediated Rhodopsin Replacement Provides Therapeutic Benefit in Mice with a Targeted Disruption of the Rhodopsin Gene
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The ability of AAV2/5 to target murine photoreceptors was used to optimize vector expression cassettes for rhodopsin replacement gene therapy in the retina. Defects in this pivotal protein in the visual cycle are associated with various forms of inherited eye defects including retinitis pigmentosa. A final optimized vector design led to functional correction and regeneration of rod outer segment in a mouse model of rhodopsin deficiency. The rhodopsin gene (RHO) encodes a highly expressed G protein-coupled receptor that is central to visual transduction in rod photoreceptors. A suite of recombinant 2/5 adeno-associated viral (AAV) RHO replacement vectors has been generated in an attempt to recapitulate endogenous rhodopsin levels from exogenously delivered AAV vectors in the retina of mice with a targeted disruption in the rhodopsin gene (Rho–/– mice). Approximately 40% of wild-type mouse rhodopsin mRNA levels (RNA taken from whole retinas) was achieved in vivo in AAV-RHO-injected eyes, representing approximately 50-fold increases in expression compared with the initial vector. The main focus of this study was to test whether expression of AAV-RHO replacement in Rho–/– mice provided therapeutic benefit, which to date had not been achieved. Rho–/– mice neither elaborate rod outer segments nor have rod-derived electroretinograms (ERGs). Our results indicate for the first time in this model that subretinal AAV-RHO delivery leads not only to RHO immunolabeling but the generation of rod outer segments as evaluated by light and transmission electron microscopy. Improved histology was accompanied by rod photoreceptor activity as assessed by ERG for at least 12 weeks postinjection. The most efficient AAV-RHO constructs presented in this study provide sufficient levels of RHO to be of therapeutic benefit in Rho–/– mice and therefore represent important steps toward generating potent AAV-RHO replacement genes for gene therapy in RHO-linked human retinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“For example, AAV2 = 2-mediated delivery of the RPE-65 gene to Briard dogs presenting with RPE-65 -linked Leber congenital amaurosis (LCA) has been shown to restore vision (Acland et al ., 2001).”
A point mutation of the rhodopsin gene in one form of retinitis pigmentosa
Dryja, T. P., McGee, T. L., Reichel, E., Hahn, L. B., Cowley, G. S., Yandell, D. W., Sandberg, M. A., & Berson, E. L. (1990) · Nature · doi:10.1038/343364a0 · Cited by 1,072 · cited 2×
“…dominant RP (adRP) (McWilliam et al ., 1989; Dryja et al ., 1990; Farrar et al ., 1990) and represents the most common gene implicated in adRP, accounting for approximately 25% of cases (McWilliam et al ., 1989; Dryja et al ., 1990; Farrar et al ., 1990, 2002; www.sph.uth.tmc.edu = RetNet = ).”
G Protein–Coupled Receptor Rhodopsin
Palczewski, K. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142743 · Cited by 764 · cited 6×
“Rho expression initiates at approximately P4 postnatally in the murine retina (McNally et al ., 1999), increasing in levels of expression until Rho comprises 90% of ROS disk membranes (Palczewski, 2006).”
InfluentialRetinopathy induced in mice by targeted disruption of the rhodopsin gene
Humphries, M. M., Rancourt, D., Farrar, G. J., Kenna, P., Hazel, M., Bush, R. A., Sieving, P. A., Sheils, D. M., Creighton, P., Erven, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-216 · Cited by 529 · cited 5×
“In summary, a significant rescue of the severe retinopathy present in Rho – = – mice (Humphries et al ., 1997; Lem et al ., 1999) was observed.”
InfluentialSelf-citationOlsson, J. E., Gordon, J. W., Pawlyk, B. S., Roof, D., Hayes, A., Molday, R. S., Mukai, S., Cowley, G. S., Berson, E. L., & Dryja, T. P. (1992) · Neuron · doi:10.1016/0896-6273(92)90236-7 · Cited by 455 · cited 1×
“Knowledge of the underlying genetic pathogenesis, together with the availability of animal models (Olsson et al ., 1992; Li et al ., 1996; Humphries et al ., 1997) and vectors for delivery, has enabled exploration of gene-based therapies for inherited retinopathies.”
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“Larger inserts of approximately 9kb have been incorporated into AAV2 = 5 (Allocca et al ., 2008), although levels of expression from these vectors have still to be fully elucidated.”
Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Regulation of photoreceptor gene expression by Crx-associated transcription factor network
Hennig, A. K., Peng, G.-H., & Chen, S. (2008) · Brain Research · doi:10.1016/j.brainres.2007.06.036 · Cited by 214 · cited 1×
“P sequences used (Hennig et al ., 2008; Oh et al ., 2008).”
Cited by
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
“This approach is being studied in mutations of rhodopsin (46, 47) and rds/peripherin (48).”
BackgroundAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
“More recently, Palfi et al. demonstrated that AAVrh10 transduces rods comparably to AAV8 in a degenerating retina.88 Using this serotype and an optimized murine rhodopsin promoter, they showed great progress in the treatment of the rhodopsin knockout mouse, compared with similar doses of AAV5.”
Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype
Han, Z., Banworth, M. J., Makkia, R., Conley, S. M., Al‐Ubaidi, M. R., Cooper, M. J., & Naash, M. I. (2015) · The FASEB Journal · doi:10.1096/fj.15-270363 · Cited by 54
“The predominant gene replacement strategy (both for rhodopsin andothergenes)utilizes cDNA(7, 8), buthavingadelivery strategy that yields properly regulated gene expression levels is especially critical because overexpression of rhodopsin is detrimental to rods (9, 10) and underexpression will yield incomplete rescue (…”
BackgroundEfficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42
Self-citationA novel retinal ganglion cell promoter for utility in AAV vectors
Hanlon, K. S., Chadderton, N., Palfi, A., Blanco Fernandez, A., Humphries, P., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00521 · Cited by 34
Self-citationPetit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
Optimized Subretinal Injection Technique for Gene Therapy Approaches
Mühlfriedel, R., Michalakis, S., Garrido, M. G., Sothilingam, V., Schön, C., Biel, M., & Seeliger, M. W. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8669-9_26 · Cited by 14
Metadata
- Authors
- Palfi, A., Millington-Ward, S., Chadderton, N., O'Reilly, M., Goldmann, T., Humphries, M. M., Li, T., Wolfrum, U., Humphries, P., Kenna, P. F., & Farrar, G. J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2010-03
- Volume
- 21
- Issue
- 3
- Pages
- 311-323
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2014611118
- Cited by
- 56
- References
- 17
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.